http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
점액성 위선암과 비점액성 위선암 및 위반지세포암종의 임상적 비교
안홍근 ( Honggeun Ahn ),정우철 ( Woo Chul Chung ),김연지 ( Yeon-ji Kim ),유성열 ( Seongyul Ryu ),임은선 ( Eunsun Lim ) 대한소화기학회 2020 대한소화기학회지 Vol.76 No.6
Background/Aims: This study examined the clinical features and prognosis of patients with mucinous gastric carcinoma (MGC), non-mucinous gastric carcinoma (NMGC), and signet ring cell gastric carcinoma (SRC). Methods: A retrospective cohort study was performed, enrolling 65 patients with MGC from January 2007 to December 2016. During the same period, 1,814 patients with histologically proven gastric cancers underwent curative or palliative operations. One hundred and ninety-five NMGC patients were selected as the 1:3 age- and sex-matched control groups. In addition, 200 SRC patients were identified. This study evaluated the demographic features of the patients, pathologic features of the tumor, and the predictive factors, such as the recurrence-free survival and overall survival. Results: The recurrence rates were significantly high in MGC than in NMGC or SRC (both p<0.01). The proportion of early gastric cancer was lower in the MGC group than in the other groups (p<0.01). In addition, metastatic lymph nodes were found more frequently in the MGC group (p<0.01), and the proportion of initial pT4, M1 stage, was highest in the MGC group. The recurrence- free survival and overall survival in the MGC group were significantly lower than those in the NMGC or SRC. Subgroup analysis showed that patients with the same American Joint Committee on Cancer (AJCC) stage of each cancer group showed a similar prognosis. Conclusions: MGC frequently presents an advanced stage with an unfavorable prognosis compared to NMGC or SRC. On the other hand, MGC of the same AJCC stage had a similar prognosis to NMGC and SRC. (Korean J Gastroenterol 2020;76:297-303)
Antiviral activity and safety of ADEFOVIL compared with HEPSERA in hepatitis B
김휘영,안홍근,김병관,김윤준,김원,정용진,이정훈,유수종,윤정환 대한내과학회 2015 대한내과학회 추계학술대회 Vol.2015 No.1
Background: Antiviral resistance is an important issue determining success or failure of the management of hepatitis B. Adefovir dipivoxil has been widely used as a combination to nucleoside analogues (NAs) in cases of resistance. The present study aimed toinvestigate the antiviral activity and safety of ADEFOVIL compared with HEPSERA. Methods: In this randomized, open-label, multi-center study, the inclusion criteria were as follows: use of NA plus HEPSERA for ≥6 months before enrollment; compensated liverdisease. Exclusion criteria were coinfection with HCV or HIV, malignancy, alcohol dependence, azotemia and pregnancy. Between December 2011 and April 2014, 123 patients were randomly assigned to either ADEVOFIL or HEPSERA, and received one of the study drugs plus NAs for 48 weeks. The primary endpoint was noninferiority of virological response of ADEFOVIL vs.HEPSERA. Results: After withdrawal of 18 patients (due to refusal), remaining 105 patients were included in the analysis (54 in ADEFOVIL (A) group and 51in HEPSERA (H) group). Baseline characteristics (age, sex, HBeAg positivity, presence of cirrhosis) showed no significant difference between the two groups. Proportions of lamivudine (LAM): telbivudine (LdT): entecavir (ETV) were 16.7%: 44.4%: 38.9% (A group) vs. 25.5%: 47.1%: 27.5% (H group). (p=0.360) Baseline HBV DNA were <20 IU/mL (<20-19,700) in A group vs. <20 IU/mL (<20-17,700) in H group. (p=0.612) Baseline ALT were 24.5 IU/L (A group) vs. 23 IU/L (H group). (p=0.629) Changes in HBV DNA (baseline-week 48) were 0.0 IU/mL (interquartile range (IQR), 0-50) in A group vs. 0.0 IU/mL (IQR, 0-81) in H group. (p=0.507) Undetectable HBV DNA at week 48 was achieved in 50.0% in A group vs. 49.0% in H group. (p=0.813) Normal ALT were observed in 74.1% of A group vs. 72.5% of H group at week 48. (p=0.631) Adverse events (AEs) were observed in 25.9% in A group vs. 21.6% in H group; most AEs were mild to moderate. Conclusions: Coadministration of ADEFOVIL with NAs showed equivalent antiviral efficacy and favorable profile of adverse events compared with HEPSERA. Considering its lower expense, ADEFOVIL could be a cost-effective alternative of HEPSERA in CHB patients with resistance to NAs.
Effectiveness of the TnR Nasal Mesh® for the Correction of Caudal Septal Deviation
이기일,안홍근,김종엽,인승민 대한이비인후과학회 부산,울산,경남 지부회 2020 임상이비인후과 Vol.31 No.2
The correction of caudal septal deviation is difficult, simply because of the intrinsic memory of the septal cartilage. We conducted a case series analysis of the effectiveness of the TnR Nasal Mesh® . This case study enrolled 3 male patients with severe caudal septal deviation. All surgical procedures were performed using endonasal septoplasty via bilateral flap elevation. Pre- and post-operative analyses of subjective symptoms were performed using the Visual Analog Scale (VAS). Nasal patency was evaluated using the objective findings of semi-quantitative endoscopy and acoustic rhinometry before and after surgery. The patients exhibited subjective and objective improvement in VAS scores, endoscopic, and acoustic rhinometry results. No significant complications were observed. We verified the clinical effectiveness of TnR Nasal Mesh® for caudal septal correction without the external open approach. We suggest that septal batten grafting with the alloplastic TnR Nasal Mesh® can be an alternative method for caudal septal correction.
Clinical Characteristics and Management of Saccular Cysts: A Single Institute Experience
김주현,김명희,안홍근,최홍식,변형권 대한이비인후과학회 2019 Clinical and Experimental Otorhinolaryngology Vol.12 No.2
Objectives. A saccular cyst is defined as a dilated saccule of the larynx, filled with mucus, and is located between the false vocal cords and the thyroid cartilage. Although this uncommon laryngeal condition is benign in nature, it could lead to dyspnea, stridor, and airway obstruction, depending on its size and location. Furthermore, some saccular cysts have been associated with laryngeal carcinoma. This study aimed to characterize this rather uncommon laryngeal condition to aid in determining the proper management of this pathology. Methods. Medical records were retrospectively reviewed of all patients with saccular cysts diagnosed and treated between 2006 and 2017 at a tertiary otolaryngologic care center. Results. Seven patients with saccular cysts were identified (male:female=2:5; mean age, 34.1 years); two were pediatric patients. Surgical intervention was performed in all patients by laryngo-microsurgery using CO2 laser. There was no recurrence after the initial surgical treatment. Conclusion. Saccular cysts can be managed endoscopically using CO2 laser, without requiring an external approach. Therefore, an endoscopic approach should be actively considered for an optimal treatment outcome.
김명희,최종중,안홍근,박중수,김연수,Kim, Myeong Hee,Choi, Jong Joong,Ahn, Hong Geun,Park, Joong Su,Kim, Yeon Soo 대한두경부종양학회 2019 대한두경부 종양학회지 Vol.35 No.1
Mucosa-associated lymphoid tissue (MALT) lymphoma has specific clinical and pathologic features. The most common site MALT lymphomas is the stomach; however, it can also occur in other organs, such as the salivary glands. MALT lymphoma is rare, but its prognosis is good. A 32-year-old man visited Konyang university hospital with parotid mass. Superficial partial parotidectomy was performed to exclude lymphoid neoplasms. IgH gene rearrangement analysis of the surgical specimen led to the diagnosis of MALT lymphoma. The patient underwent esophagogastroduodenoscopy, positron emission tomography-computed tomography, and whole-body bone scan. Regional or distant metastasis was not observed on staging workup. The patient underwent postoperative radiation therapy, there has been no recurrence of MALT lymphoma to date. Here, we report this rare case of parotid MALT lymphoma that was treated with surgery and postoperative radiation therapy.
김성수,나현수,안홍근,박한삼,설재웅,조일훈 대한의생명과학회 2023 Biomedical Science Letters Vol.29 No.4
This study emphasizes the importance of early diagnosis and response to COVID-19, leading to the development of a rapid diagnostic kit using quantum dots. The research focuses on finely tuning bioconjugation with quantum dots to enhance the accuracy and sensitivity of COVID-19 diagnosis. We have developed a COVID-19 rapid diagnostic kit that exhibits a sensitivity more than 50 times higher than existing COVID-19 diagnostic kits. Quantum dots enable the accurate detection of COVID-19 viral antigens even at low concentrations, providing a rapid response in the early stages of infection. The COVID-19 quantum dot diagnostic kit offers quick analysis time, utilizing the quantum properties of particles to swiftly measure COVID-19 infection for immediate response and isolation measures. Additionally, this diagnostic kit allows for multiple analyses with ease, as multiple quantum dots can detect various antigens and antibodies simultaneously in a single experiment. This efficiency enhances testing, reduces sample requirements, and lowers experimental costs. The application of this diagnostic technology is anticipated in the future for early diagnosis and monitoring of other infectious diseases.
Trimethoprim-sulfamethoxazole에 대해 지연성 과민반응을 보인 환자에서 성공적인 급속 탈감작 치료 사례 1예
윤도란 ( Doran Yoon ),안홍근 ( Hongkeun Ahn ),김세용 ( Se Yong Kim ),황성준 ( Seong Jun Hwang ),박한기 ( Han Ki Park ),강혜련 ( Hye Ryun Kang ) 대한천식알레르기학회(구 대한알레르기학회) 2015 Allergy Asthma & Respiratory Disease Vol.3 No.2
Trimethoprim-sulfamethoxazole (TMP-SMX) is an antibiotic used for the treatment or prophylaxis of Pneumocystis pneumonia and other infectious conditions. Sulfonamide derivatives have been reported to cause delayed hypersensitivity reactions, resulting in switch to less effective second-line antibiotics. Although desensitization is traditionally known to be effective in patients with imme¬diate hypersensitivity, it is also applied to the treatment of delayed hypersensitivity in recent years. A 66-year-old female who had a history of repeated TMP-SMX-induced delayed hypersensitivity presenting as whole body rashes needed to take prophylactic dose of TMP-SMX (80/400 mg daily) before initiation of chemotherapy for multiple myeloma. Intravenous rapid desensitization was per¬formed by using a 11-step, 4-bottle protocol from 1:1,000 to 1:1 solution for 3 hours to reach the target dose for prophylaxis. After successful rapid desensitization of TMP-SMX, 1-month prophylaxis was completed without any complications until the patient re-covered normal immunity. We herein reported a case of delayed hypersensitivity reaction to TMP-SMX in an about-to-be immuno¬compromised host with planned chemotherapy who successfully completed 1-month prophylaxis with the drug without any com¬plications through rapid desensitization.(Allergy Asthma Respir Dis 2015;3:155-158)